Phathom Pharmaceuticals is focusing on gastroenterologists to increase adoption of its drug VOQUEZNA, aiming for sustainable profitability. The company reported an 88% revenue increase to $74.3 million in Q2 2026, with reduced selling expenses and expects full-year revenue between $310 million and $325 million, maintaining an 80% gross margin. Supported by $182.5 million in cash and improved cash flows, Phathom faces risks from revenue-interest financing and competition from tegoprazan. Key growth drivers include rising covered prescriptions, disciplined spending, and development of as-needed dosing.
Korn Ferry reported strong Q1 results with earnings per share of $1.43 and revenue of $756.5 million, both exceeding analyst expectations and marking continued growth. Despite this, the stock fell due to conservative guidance for the next quarter, wh...
SailPoint reported Q2 2026 earnings with revenue of $308.81 million, slightly below estimates but up 17% year-over-year. Adjusted EPS of $0.09 beat analyst expectations by 12.5%, reflecting improved profitability. The company showed strong subscripti...
The Cooper Companies is set to report its Q3 2026 earnings with analysts expecting earnings per share (EPS) of $1.12 and revenue of $1.10 billion, both showing growth from the previous year. Despite a recent 2.7% drop in stock price to $67.69, an ana...
Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...
Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...
